The c-myb proto-oncogene encodes a nuclear phosphoprotein that plays a crucial role in normal hematopoiesis. It is a short-lived transcription factor rapidly degraded by the 26S proteasome. Although it has been shown that instability determinants reside in its carboxyl terminus, the molecular mechanism of c-Myb degradation is unknown. Here, we report the ®rst evidence that phosphorylation plays a role in targeting the protein to the proteasome. Inhibition of cellular serine/threonine protein phosphatase activity by okadaic acid resulted in hyperphosphorylation of c-Myb and extremely rapid turnover. The hyperphosphorylation resulted in a protein with altered properties that was indicative of conformational changes. Its mobility on gel electrophoresis was altered as well as its recognition by speci®c monoclonal antibody. The altered hyperphosphorylated protein still bound to DNA with an anity similar to that of the hypophosphorylated form. Phosphorylation of three previously identi®ed sites, serines 11, 12, and 528, does not appear to be involved in the proposed changes in conformation or stability. However, phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased c-Myb phosphorylation mainly on threonine residues that correlated with other okadaic acid-induced alterations of c-Myb. These ®ndings indicate that Ser/Thr phosphatases prevent conformational changes that may play an important role in controlled degradation of c-Myb.
Introduction
The c-myb proto-oncogene encodes a highly conserved 75 ± 80 kDa transcription factor which is expressed predominantly in immature cells of hematopoietic origin (Wol, 1996; Weston, 1998) . Analyses of deletion mutants performed in several laboratories have established a functional map of c-Myb. It consists of an NH2-terminal DNA-binding domain (Klempnauer and Sippel, 1987; Biedenkapp et al., 1988; Sakura et al., 1989) , a central acidic transactivation domain (Nishina et al., 1989; Weston and Bishop, 1989; Ibanez and Lipsick, 1990 ) and a COOH-terminal negative regulatory domain (Sakura et al., 1989; Kalkbrenner et al., 1990) . The DNA-binding domain is the most conserved region among Myb family members and is comprised of three imperfect repeats (R1 ± 3) of 50 ± 52 amino acids each (Sakura et al., 1989; Howe et al., 1990) . The second and third repeats recognize and speci®cally bind to the consensus sequence PyAAC(G/T)G (Biedenkapp et al., 1988; Howe and Watson, 1991; Ogata et al., 1996) . A highly hydrophilic transactivation domain is required for increased transcription of reporter genes (Sakura et al., 1989; Kalkbrenner et al., 1990) . This region of cMyb interacts with the coactivator CBP, a histone acetyltransferase, which serves to bridge c-Myb to the basal transcription machinery (Dai et al., 1996; Oelgeschlager et al., 1996) . The ability to transactivate target genes is also regulated through a large negative regulatory domain. Within this region the putative leucine zipper motif has been identi®ed as a region capable of binding cellular cofactors that modulate the activity of the protein (Kanei-Ishii et al., 1992; Tavner et al., 1998) . In addition, the EVES motif located in the COOH terminus has been suggested to modulate the activity of c-Myb by inhibiting the binding of p100 to the DNA-binding domain (Dash et al., 1996) .
Post-translational modi®cation of transcription factor, such as c-Myb, can modulate regulatory activity through changes in subcellular localization, DNAbinding anity, transactivation potential and proteolytic stability (Calkhoven and Ab, 1996) . c-Myb is phosphorylated at multiple sites in vivo (Bading et al., 1989; Luscher et al., 1990; Aziz et al., 1995) and at least some of these sites have been demonstrated to be physiologically important. Serines 11 and 12, located in the NH2 terminus, have been identi®ed as phosphorylation sites in vivo and are phosphorylated by caseine kinase II (CKII) in vitro (Luscher et al., 1990) . Phosphorylation of these residues results in a decrease in sequence speci®c binding to DNA and also inhibits cooperativity with the transcription factor NF-M (Luscher et al., 1990; Oelgeschlager et al., 1995) . Ser 528 (murine numbering, Bender and Kuehl, 1986) , which is in the negative regulatory domain, is also phosphorylated in vivo by the 42 kDa MAP kinase or another related proline directed kinase (Aziz et al., 1995) . Ser to Ala substitution at this site results in an increased ability of c-Myb to activate transcription from some, but not all Myb-responsive promoters (Miglarese et al., 1996) . It was also reported that phosphorylation of c-Myb increases during mitosis and c-Myb isolated from mitotic cells lost the ability to bind DNA, suggesting that changes in phosphorylation status may alter c-Myb activity during the cell cycle (Luscher and Eisenmann, 1992) .
The steady state level of any protein is the result of the balance between the rates of its production and degradation. We previously showed that c-Myb is degraded by the 26S proteasome in hematopoietic cells, and that the region responsible for its very short halflife is located in the COOH-terminus (Bies and Wol, 1997; Bies et al., 1999) . In the present study, we looked at the eect of phosphorylation on the proteolytic processing of the protein by examining its turnover in cells treated with okadaic acid (OA), an inhibitor of cellular Ser/Thr protein phosphatases. Treatment of cells with OA resulted in rapid c-Myb hyperphosphorylation, altered properties suggesting conformational changes, and accelerated turnover of the protein by the 26S proteasome. Phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased phosphorylation mainly on threonine. We concluded that OA-sensitive protein phosphatases regulate c-Myb activity through modulation of the protein half-life.
Results

Treatment of M1 myeloid cells with inhibitors of Ser/Thr protein phosphatases induces hyperphosphorylation and increased proteolytic turnover of c-Myb
Protein phosphorylation is maintained through the balanced activities of protein kinases and phosphatases. To determine if alteration of the phosphorylation state of the cell aects the stability of c-Myb, we treated myeloblastic M1 cells with okadaic acid (OA), a potent cell permeable inhibitor of serine/threonine phosphatases. In the ®rst experiment, 1 mM OA was added during pulse labeling and was present throughout the entire chase. At the indicated time points, c-Myb protein was immunoprecipitated, separated by polyacrylamide gel electrophoresis, and analysed by¯uor-ography. As shown in Figure 1 , OA treatment of M1 cells caused a dramatic decrease in c-Myb protein expression to the point where it was undetectable. However, simultaneous treatment of cells with OA and ALLN, an inhibitor of 26S proteasome, restored immunoprecipitable c-Myb. The protein obtained in the presence of both inhibitors showed a reduced electrophoretic mobility on SDS ± PAGE. Treatment of immunoprecipitated c-Myb in vitro with calf intestinal phosphatase restored its normal mobility, suggesting that slower migration of c-Myb was due to phosphorylation-induced conformational changes (Figure 1a ). The proteolytic processing was so ecient in this experiment that we were unable to calculate the halflife of the hyperphosphorylated form of c-Myb. For this reason, we set up a pulse chase experiment, where OA was added only at the end of the pulse, instead of throughout the pulse. Cells were immediately chased and the level of radio-labeled c-Myb was analysed by immunoprecipitation and¯uorography. As shown in Figure 1b , the stability of c-Myb was signi®cantly reduced immediately after OA addition. In OA-treated cells, after a 60 min chase, we detected less than 10% of the protein, whereas in untreated cells we were able to detect more than 50%. A similar eect was observed when M1 cells were treated with calyculin A, another inhibitor of Ser/Thr phosphatases (data not shown).
To explore the kinetics of hyperphosphorylation and degradation of c-Myb in cells after inhibition of Ser/ Thr phosphatases, we treated COS7 cells, expressing full-length c-Myb (FL-c-Myb), with OA for various lengths of time. Cells were lysed and protein lysates were subjected to Western blot analyses using anti-c- S-methionine/cysteine and chased for the indicated time. Okadaic acid (OA, 1 mM), an inhibitor of Ser/Thr phosphatases and ALLN (100 mM), an inhibitor of the 26S proteasome, were added to the cells at the beginning of the pulse and were present during the entire chase. The control cells were treated with the vehicle (DMSO, 0.5%). cMyb proteins were immunoprecipitated, separated on an 8% SDS ± PAGE and visualized by¯uorography as described in Materials and methods. Some immunoprecipitates, as indicated, were also treated in vitro with calf intestinal phosphatase (CIP) to remove phosphates from modi®ed amino acids. The mobilities of prestained molecular weight standards in kDa are indicated on the left. (b) M1 cells were metabolically labeled and okadaic acid (OA, 1 mM) was added only during the chase. At the indicated times c-Myb was immunoprecipitated and analysed as described in Figure 1 . Quantitative analysis was performed on a PhosphorImager 425 and IMAGEQUANT software. Each point on the graph represents the relative amount of c-Myb during the pulse-chase experiment; the level of protein at the end of pulse was assigned to 100% Myb antibody. Representative results are shown in Figure 2 . The ®rst appearance of a slower migrating form of c-Myb occurred between 10 and 15 min after the start of OA treatment. Ninety minutes of treatment with the inhibitor caused a signi®cant decrease in the level of protein. Since the dierence in size appears to be greater than expected to result from the addition of phosphate groups we suggest that hyperphosphorylation results in conformational changes. This would imply further that phosphorylation-induced conformational changes in c-Myb precede its accelerated proteolytic processing. In addition, co-treatment of OA with either an inhibitor of protein synthesis, cycloheximide (CHX), or an inhibitor of mRNA synthesis, actinomycin D (ActD), did not block phosphorylation-induced alterations in mobility and degradation of c-Myb (Figure 2) . Furthermore, treatment with CHX or ActD alone did not cause any change in the mobility of the protein. Therefore mRNA or protein synthesis are not required for the observed eect of OA on the conformation and stability of c-Myb.
Further evidence for OA-induced conformational changes in c-Myb
As mentioned above, we observed that hyperphosphorylated c-Myb had a decreased mobility in PAGE. Further support for the phosphorylation-induced conformational changes came from an analysis of accessibility of domains of the protein to monoclonal antibodies. Western blotting was performed using lysates from OA treated or untreated COS7 cells. Although monoclonal antibodies directed against the NH 2 terminus (aNH 2 -Myb) and the COOH-terminus (aCT-Myb) strongly recognized the protein from untreated cells, there was a pronounced dierence in the reactivity of the domain speci®c monoclonals to the protein from OA-treated cells (Figure 3 ). The monoclonal antibody raised against the NH 2 terminus of cMyb reacted strongly with the most slowly migrating, hyperphosphorylated form of Myb from OA-treated cells, whereas the antibody raised against the COOHterminus did not ( Figure 3 ). These results indicate that c-Myb can respond to its phosphorylation status by conformational alterations that inhibit access to the carboxyl terminus.
We wanted to test whether hyperphosphorylated Myb could bind to DNA and, if it was bound, whether it adopted a dierent conformation on DNA than hypophosphorylated c-Myb. For this purpose we performed an electromobility shift assay (EMSA) using cell lysates prepared from transfected COS7 cells. Mild conditions for preparation of cell lysates were used to avoid protein denaturation . As shown in Figure 4a , a single DNA-protein complex was formed as detected in EMSA following incubation of the MRE-A DNA with extracts prepared from COS7 cells expressing c-Myb in the absence of OA treatment. The presence of c-Myb in the complex was demonstrated by a supershift after incubation of the EMSA reaction in the presence of monoclonal anti-cMyb antibody (against the COOH terminus of murine c-Myb, Upstate Biotechnology). In addition, rabbit polyclonal anti-c-Myb antiserum (directed against the DNA-binding and transactivation domains of murine c-Myb; Bies et al., 1996) blocked the binding of MRE-A to c-Myb. There was no change in the mobility or intensity of the protein-DNA complex when rabbit preimmune serum was used in the reaction (Figure 4a ). The speci®city of this binding reaction was demonstrated by a cold competition assay, where preincubation of lysates with 20-and 100-fold excess of unlabeled MRE-A oligonucleotide diminished the detection of c-Myb-32 P-labeled MRE-A complex (Figure 4a) . To speci®cally examine the eect of hyperphosphorylation on c-Myb's ability to bind MRE-A, we prepared cell lysates from COS7 cells expressing FLMyb treated with OA and ALLN (to prevent degradation of the hyperphosphorylated protein) or ALLN alone. c-Myb from OA-treated or untreated cells was able to bind DNA with almost identical eciency. The similar DNA binding of hypo-and hyperphosphorylated forms indicates that the increased phosphorylation does not cause its release from DNA in cells as a prerequisite for increased degradation ( Figure 4b ). In addition, the use of an anti-c-Myb monoclonal antibody that recognizes an epitope in the COOH terminus suggested further that a unique conformation of the protein may be formed in cells treated with OA. As shown in Figure 4b , MRE-c-Myb complex involving the hypophosphorylated form of cMyb was completely shifted by aCT-Myb antibody, whereas only 35% of the hyperphosphorylated com- plex was shifted in the same reaction. This suggests that the aCT-Myb antibody cannot recognize some phosphorylation-induced forms of c-Myb.
Comparison of wild-type and mutant forms of c-Myb
c-Myb is known to be phosphorylated on Ser11, 12 or 528 in vivo (Bading et al., 1989; Luscher et al., 1990; Aziz et al., 1995) , however, it has not been determined whether this posttranslational modi®cation aects its proteolytic stability. To address this question, we compared the half-lives of wild-type (wt) protein with that of mutants where Ser 11, 12 or 528 had been replaced with alanine to prevent phosphorylation (FLMyb(S11,12A); FL-Myb(S528A)). We also included in this experiment a COOH-terminally truncated form of cMyb CT6-MybD(266aa) (Bies et al., 1999) , which is missing the leucine zipper and negative regulatory domain and resembles the stable oncogenic form of cMyb expressed in leukemia (Bies and Wol, 1997) . For these experiments we used COS7 cells, because the protein can be transiently expressed at high levels and cMyb is degraded by the 26S proteasome in these cells at a rate similar to that observed in hematopoietic cells (Bies et al., 1999) . Exponentially growing COS7 cells, transiently transfected with plasmid DNAs containing wt c-Myb and mutants, were metabolically labeled 36 h after transfection and chased in complete medium either in the presence or the absence of OA. The stabilities of wt and mutated forms of the protein were analysed by immunoprecipitation ( Figure 5 ). The CT6-MybD(266aa) had a marked increase in resistance to the proteasome compared to wt or the other mutants and, in addition, it was not in¯uenced by OA treatment. Quanti®cation of these data revealed that, after a 90 min chase, more than 65% of CT6-MybD(266aa) protein remained in the presence or absence of OA. In contrast, the phosphorylation mutants behaved like wt with about 30% of the protein remaining after 90 min, in the absence of OA treatment, and less than 10% in the presence of OA. Therefore, the more stable form of c-Myb with a deleted COOH-terminus (Bies et al., 1999) is also resistant to the eects of OA treatment. In addition, phosphorylation of serines 11, 12, or 528 is not required for the observed increase in c-Myb turnover. We also found that mobility changes following hyperphosphorylation were identical for wt FL-Myb and FL-Myb(S11,12A) and FLMyb(S528A) mutants ( Figure 6 ).
Inhibition of Ser/Thr phosphatases in cells increases the phosphorylation of c-Myb on Thr residues
To compare the state of c-Myb phosphorylation in cells untreated or treated with a Ser/Thr protein phosphatase inhibitor, transiently transfected COS7 cells were metabolically labeled with 32 P-orthophosphate in phosphate-free medium for 6 h. Immunoprecipitated protein from 32 P-labeled cells treated with OA and ALLN (to prevent degradation of hyperphosphorylated forms of c-Myb) or ALLN alone were fractionated by SDS ± PAGE, transferred to the membrane and analysed by direct exposure to X-ray ®lm. As expected, inhibition of phosphatases in conjunction with proteasome inhibition resulted in the appearance of a slower migrating form of 32 Plabeled c-Myb. There was, in addition, an increase in Figure 7a ). Next, we looked at which amino acids of the protein were phosphorylated in cells treated with OA and ALLN or ALLN alone. Phosphorylated proteins were hydrolyzed and phosphoamino acid analysis was performed as described in Materials and methods. As presented in Figure 7b , there was an obvious increase in the phosphorylation of Thr residues as a result of OA treatment. Quantitative analyses of phosphoamino acid contents on TLC plates revealed that the increase in phosphorylation of threonine residues in the hyperphosphorylated form of Myb was more than 350%. We then determined whether the increased stability of the COOH-terminally truncated mutant CT6-MybD(266aa) ( Figure 5 ) correlated with a loss of phosphorylation on Thr. As shown in Figure 7c the ratio of phosphorylated serines and threonines in FL-Myb and a less truncated mutant CT4-MybD(151aa) was similar. However, there was a 35% decrease in Thr phosphorylation of the CT6-MybD(266aa) protein (for quantitation, the level of PThr was normalized to the level of P-Ser; this may actually give an understimate of the per cent decrease P-Thr if P-Ser levels decreased somewhat as well). The region of murine c-Myb spanning amino acids 371 ± 485 is highly conserved among c-Myb proteins from dierent species and could contain a threonine residue which is phosphorylated in cells after inhibition of Ser/ Thr phosphatases and could be responsible for initiating of c-Myb targeted degradation. To test this hypothesis, we constructed individual mutants in which one of 11 Thr were mutated to Ala and tested for alterations in mobility and proteolytic stability. All of the 11 mutated c-Myb proteins had similar proteolytic half-lives as wt c-Myb in untreated or OA treated cells (data not shown), suggesting that modi®cation of any single Thr residue in this region has no eect on stability of c-Myb. However, we cannot rule out the Figure 5 The COOH-terminal region of c-Myb is required for okadaic acid-induced degradation. COS7 cells transiently expressing FL-Myb, FL-Myb(S11,12A), FL-Myb(S528A) or CT6-MybD(266aa) were metabolically labeled and analysed in a pulse-chase experiment in the presence or absence of okadaic acid (OA, 1 mM). DMSO was used at the concentration 0.5% in control reactions. The gels were quantitatively analysed as described in Figure 2 . Each bar on the graph represents the relative amount of c-Myb after 90 min of chase. The level of protein at the beginning of the pulse was assigned to 100% Figure 6 Mutation of serine 11, 12, or 528 to alanine does not prevent the hyperphosphorylation-induced conformational changes in c-Myb caused by OA treatment. COS7 cells, transiently transfected with FL-Myb, FL-Myb(S11,12A), or FLMyb(S528A) were untreated (7) or treated (+) with OA (1 mM) together with ALLN (100 mM) for 90 min and lysed. Protein samples were separated by SDS ± PAGE, transferred to a nitrocellulose membrane, probed with anti-c-Myb monoclonal Ab (aNH 2 -Myb) and developed using an ECL kit (Amersham) possibility that multiple phosphorylation sites are required for the observed mobility changes and destabilization of protein.
To determine if treatment of cells within OA resulted in phosphorylation of new sites in c-Myb, or increased the stochiometry of residues that were already phosphorylated, hypo-and hyperphosphorylated forms of c-Myb were digested with trypsin and the resulting peptides were separated by reverse-phase HPLC as described in Materials and methods. Separated peptides were monitored for radioactivity by Cerenkov counting. As shown in Figure 8 , similar pro®les of radioactive tryptic peptides were obtained from the hypo-and hyperphosphorylated forms of c-Myb. This result implies that OA increased the level of phosphorylation of c-Myb on amino acid residues already modi®ed in untreated cells rather than inducing de novo sites of phosphorylation. Therefore, OA induced a quantitative change in the phosphorylation of c-Myb. Obvious increases in radioactivity were observed in fractions 26, 46, and 52. We also found decreased radioactivity in fractions 22 and 38 ± 42, which could be a consequence of surface alterations due to the hyperphosphorylation of c-Myb. Phosphoamino acid analysis of peptides in fractions revealed that peptides in fractions 26 and 52 were phosphorylated on Thr. The peptide in fraction 26 contained only phospho-Thr and the one in 52 was phosphorylated on both Ser and Thr (data not shown). Phosphoamino acid analyses together with tryptic peptide mapping of hyperphosphorylated c-Myb suggest that there is more than one phosphorylated Thr residue in cells under strict control of Ser/Thr phosphatases.
Discussion
Over the last few years, phosphorylation has been implicated in the control of DNA-binding and transactivation activity of c-Myb (Bading et al., 1989; Luscher et al., 1990; Aziz et al., 1995; Miglarese et al., 1996) . In data presented here, we have demonstrated for the ®rst time that hyperphosphorylation of c-Myb results in an altered form with a slower mobility in gel electrophoresis and this alteration is correlated temporally with its rapid degradation by the 26S proteasome. It was established in our laboratory previously, that the 26S proteasome is responsible for the degradation of c-Myb (Bies and Wol, 1997) . This study provides new insight into the mechanism involved in the targeting of the protein to this multimeric proteolytic complex.
On the basis of these studies we speculate that hyperphosphorylation-induced conformational changes in c-Myb may expose epitopes on the surface of the protein that are required for recognition and proteolytic processing. Alternatively, phosphorylation site(s) under strict control of a putative Ser/Thr phosphatase could directly serve as a recognition signal for the proteolytic machinery. There are several examples where phosphorylation of speci®c amino acids in a protein substrate triggers an enzymatic cascade ultimately leading to destruction by proteasome. For example site speci®c Pi-orthophosphate for 6 h. ALLN alone, or together with OA, was added for the last 2 h and cells were lysed as described in Materials and methods. Won and Reed, 1996) , cyclin D1 (Diehl et al., 1997) and inhibitor p27
Kip1 (Vlach et al., 1997) marks these regulators of the cell cycle for modi®cation by ubiquitin and rapid degradation by the 26S proteasome. The speci®city of this process is achieved by the recently identi®ed group of proteins found in ubiquitin ligase complexes. These proteins contain conserved structural motifs such as WD40 or WW, which can directly bind phosphorylated Ser or Thr residues and recruit other proteins necessary for destruction of the substrate by the 26S proteasome (Laney and Hochstrasser, 1999; Koepp et al., 1999) .
Our data suggest that conformational changes in cMyb after OA treatment are required for accelerated proteolytic processing of c-Myb. The slower mobility of c-Myb on SDS ± PAGE was detected much earlier than increased proteolytic processing. In addition, fulllength c-Myb underwent a more dramatic structural alteration than the more stable CT6-MybD(266aa). Results from phosphoamino acid analyses and tryptic peptide mapping suggest phosphorylation of more than one Thr residue in c-Myb after OA treatment. Phosphoamino acid analyses of tryptic peptides of hyperphosphorylated protein identi®ed phosphorylated Thr residues in two separate fractions. We also detected a decrease in Thr phosphorylation by removing sequences between 371 aa (CT6-Myb-D(266aa) and 485 aa (CT4-MybD(151aa). The region between aa 371 ± 485 is very conserved and contains several Thr residues which are potential phosphorylation sites for dierent protein kinases. In regard to this, it was reported by Aziz et al. (1993) that unidenti®ed Thr residue(s) in this region can be phosphorylated in vitro by p42 mapk . Also, we observed that truncation in this region results in its increased half-life (Bies et al., 1999) . Therefore, we focused on this region and prepared mutants of all 11 Thr. However, mutation of any single Thr from the region spanning aa 371 ± 485 failed to stabilize or prevent phosphorylationinduced mobility changes of c-Myb protein after treatment of cells with OA (data not shown). Therefore, we can hypothesize that phosphorylation of more than one residue may be required for the proposed conformational changes. Alternatively, phosphorylation in the amino terminus may result in a conformational change which aects the carboxyl-terminal part of the protein. Finally, we cannot completely rule out the possibility that a c-Myb interacting protein is phosphorylated and responsible for its degradation.
It was suggested previously that c-Myb is capable of adopting an alternative conformation (Ness, 1996) . The EVES motif in COOH-terminus can interact with the DNA binding domain of c-Myb and this intramolecular interaction and consequent conformational change can aect the function of c-Myb as a transcriptional activator. This intramolecular interaction can be competitively inhibited by binding of p100 protein which contains an identical EVES motif (Dash et al., 1996) . Experiments with linker insertion mutants in the carboxyl terminus also implied that conformational changes are important in regulation of c-Myb activity (Dubendor and Lipsick, 1999) . That the COOHterminus can adopt an open conformation and be sensitive to proteolysis when bound to DNA is in agreement with in vitro proteolytic clipping experiments. The COOH-terminus of c-Myb has been identi®ed as the most sensitive region to the enzymatic activity of endoproteinase Glu-C, trypsin or chymotrypsin Bies and Wol, unpublished result) . Phosphorylation-dependent conformational changes could expose hydrophobic surfaces otherwise hidden in the protein. This region, once exposed on the surface, could directly serve as a recognition signal for proteolytic machinery, or cause a switch between more than one interacting protein partner in cells. It has been proposed that some proteins contain a surface of prefolded structure that is an important determinant for degradation. This is exempli®ed by the yeast mating type transcription factor a2 (reviewed in Laney and Hochstrasser, 1999) and is in contrast to the short peptide sequences de®ned for recognition of proteins such as IkBa (Chen et al., 1995; Brown et al., 1995) . Thr phosphorylation of c-Myb in vivo during mitosis was demonstrated previously (Luscher and Eisenman, 1992) . However, the relationship of this result to ours is unclear. They reported that c-Myb isolated from chicken pre-B cell lymphoma arrested with nocodazole in G2/M phase of cell cycle was phosphorylated on unidenti®ed Thr residue(s) and also did not bind DNA. In contrast, we demonstrated that the hyperphosphorylated c-Myb from OA treated cells was able to bind MRE-A with an apparent anity similar to that of the hypophosphorylated form. However, one cannot exclude the possibility that the protocol used for puri®cation of mitotic c-Myb in the other study could cause the irreversible denaturation of the hyperphosphorylated form of c-Myb, as DNA binding activity could not be rescued by phosphatase treatment in vitro (Luscher and Eisenman, 1992) . In regard to phosphorylation during mitosis, we have been unable to detect a signi®cant dierence in the half-life of c-Myb protein isolated either from interphase or nocodazole treated M1 cells (J Bies and L Wol, unpublished observations).
Our ®ndings on the increased stability of the COOHtruncated protein is intriguing in light of results from several laboratories that COOH-terminally truncated cMyb exhibits increased DNA binding anity, transactivation and transforming capacity (Sakura et al., 1989; Hu et al., 1991; Grasser et al., 1991; Dash et al., 1996) . The mechanism through which NRD exerts its negative eect on these activities is not clear. Also, several cellular proteins capable of binding to the NRD of cMyc were detected (Kanei-Ishii et al., 1992; Tavner et al., 1998) . What role, if any, these interactions play in determining the half-life of c-Myb is not clear at present and will require further experimentation.
In summary, our data demonstrate that disruption of a phosphorylation pathway has a signi®cant eect on the phosphorylation of c-Myb and its half-life. Studies are in progress to precisely map phosphorylated Thr residue(s) in c-Myb and to determine their role in the proposed conformational changes and subsequent degradation.
Materials and methods
Cell lines and culture conditions
The murine myeloid leukemia cell line, M1 (Liebermann and Homan-Liebermann, 1989) , was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum. COS7 cells (simian virus 40 large T antigen transformed CV-1 cells) were cultured in Dulbecco's modi®ed Eagle medium (DMEM) with 10% fetal calf serum. The inhibitors of Ser/Thr phosphatases, the 26S proteasome, RNA synthesis, and protein synthesis were used in the cell culture experiments as described in the ®gure legends and Results section.
Reagents
The peptide aldehyde N-acetyl-L-leucinyl-L-leucinyl-norleucinal (ALLN, Sigma) and okadaic acid (OA, Sigma) were dissolved in DMSO and used at concentrations of 1 mM and 100 mM, respectively. The inhibitor of protein synthesis, cycloheximide (CHX, Sigma), and RNA synthesis, actinomycin D (ActD, Sigma), were dissolved in PBS and used at the indicated concentrations.
Plasmid constructs
The expression vector encoding murine c-Myb under the control of CMV promoter was prepared by subcloning a 2 kb BamHI ± XbaI fragment of murine c-myb cDNA (Bender and Kuehl, 1986 ) into pcDNA3.1(+) vector (Invitrogen). Premature termination mutants CT4-MybD(151aa) and CT6-MybD(266aa) were constructed as described previously (Bies et al., 1999) . A vector containing the mutant of c-Myb, where serines 11, 12 was replaced with alanines FL-Myb(S11,12A) was kindly provided by Bernard Luscher (Medizinische Hochschule Hannover, Hannover, Germany) and a construct containing mutant of serine 528 to alanine FL-Myb(S528A) was provided by Tim Bender (University of Virginia, Charlottesville, Virginia).
Transient transfection
Plasmids encoding c-Myb proteins were transiently transfected into COS7 cells using DOSPER liposomal transfection reagent (Boehringer Mannheim) according to the manufacturer's instructions. Brie¯y, COS7 cells were plated at 3610 5 cells per 100 mm dish 1 day prior to transfection. The following day, the medium was changed and cells were transfected with 10 mg of plasmid DNA and 30 ml of DOSPER reagent. Protein analyses were performed 36 ± 48 h post-transfection.
Metabolic labeling of proteins, immunoprecipitation and gel electrophoresis
Protein stability was evaluated in a pulse-chase experiment as described previously (Bies and Wol, 1997) . Brie¯y, the cells were starved in methionine/cysteine free medium, labeled for 45 min (pulse) with Trans 35 S label (ICN) and chased in prewarmed complete medium without radioactive amino acids. At the indicated times, the cells were disrupted in cold lysis buer (20 mM Tris-HCl [pH 7.5], 50 mM NaCl, 0.5% NP40, 0.5% SDS, 0.5% sodium deoxycholate) supplemented with a mix of proteases inhibitors (Complete TM , Boehringer Mannheim), sonicated and immunoprecipitated with rabbit anti-cMyb antiserum (Bies et al., 1996) . Immunocomplexes were separated by SDS ± PAGE on an 8% gel and visualized bȳ uorography. Quantitative analyses of radioactive signals were performed on a PhosphorImager 425 using IMAGE-QUANT software (Molecular Dynamics).
Immunoblotting
Untreated cells or cells treated with an inhibitor of Ser/Thr protein phosphatases, OA, and an inhibitor of the 26S proteasome, ALLN, for the indicated times, were washed twice in phosphate-buered saline, and lysed in lysis buer supplemented with a cocktail of protease inhibitors (Complete TM ) as well as the phosphatase inhibitors sodium¯uoride (50 mM), sodium pyrophosphate (30 mM) and sodium orthovanadate (100 mM). Cell lysates were sonicated, centrifuged at 13 000 r.p.m. for 15 min at 48C and protein extracts were fractionated by SDS ± PAGE on an 8% gel and electrophoretically transferred to a nitrocellulose membrane (Schleicher & Schuell) . Immunoblots were incubated with anti-c-Myb monoclonal antibodies (a kind gift from Tim Bender, University of Virginia, Charlottesville, Virginia and purchased from Upstate Biotechnology) and detected using an ECL kit (Amersham) in accordance with the manufacturer's instructions.
Phosphoamino acid analysis and tryptic peptide mapping
Phosphoamino acid analysis was performed as described previously (Biesova et al., 1997) . COS7 cells, transiently expressing full-length c-Myb, were rinsed twice with Trisbuered saline (20 mM Tris-HCl [pH 7.4], 137 mM NaCl, 2.7 mM KCl) and labeled in phosphate-free Dulbecco's modi®ed Eagle medium with 0.5 mCi/ml carrier-free 32 Pi orthophosphate (ICN) for 6 h. During the last 90 min of metabolic labeling, the cells were treated with OA (1 mM) and ALLN (100 mM) or ALLN alone. Phosphorylated forms of cMyb were immunoprecipitated, fractionated on SDS ± PAGE and transferred to an Immobilon-P membrane (Millipore). The part of the membrane with immobilized 32 P-labeled cMyb protein was excised and hydrolyzed in 200 ml of 6N HCl (constant boiling) (Sigma) at 1108C for 2 h. Hydrolyzed samples were diluted with water, frozen in dry ice, lyophilized in a Speedvac (Savant), and resuspended in 10 ml of water containing 0.1 mg/ml of each phosphoamino acid standard, phosphoserine, phosphothreonine and phosphotyrosine (Sigma). The samples were spotted onto thin-layer cellulose plates (Sigma) and subjected to electrophoresis at 48C in pH 3.5 buer (pyridine-glacial acetic acid-water, 5 : 50 : 945) for 1 h at 950 V. The migration of phosphoamino acid standards was revealed by staining with ninhydrin (Sigma) and 32 Plabeled phosphoamino acids were visualized by autoradiography.
For tryptic peptide mapping, immunoprecipitated 32 Plabeled c-Myb protein was separated on SDS ± PAGE and transferred to the nitrocellulose membrane (Schleicher & Schuell) . The piece of membrane with immobilized c-Myb was incubated for 30 min at 378C in 0.5% PVP-360 100 mM acetic acid, extensively washed in 50 mM ammonium bicarbonate and digested in the same buer with 10 mg of TPCK-trypsin (Sigma) for 2 h at 378C. Peptides were diluted with water, frozen in dry ice and lyophilized in a Speedvac (Savant). Lyophilized peptides were dissolved in water and analysed by reversed-phase HPLC (Hewlett-Packard 1090L) using a narrow bore C-8 column (2.16250 mm, 5 micron particle size; Advantage) and a water-acetonitrile gradient (5 ± 60% in 1 h) in the presence of 0.1% TFA. Absorbance from 200 ± 600 nm was monitored continuously using a Waters 996 photodiode array detector. Fractions were collected at 1 min intervals and radioactivity measured by Cerenkov counting.
Electrophoretic gel mobility shift assay (EMSA)
EMSA with COS7/FL-Myb cell lysates was performed as described by Oelgeschlager et al. (1995) . Brie¯y, COS7 cells expressing the c-Myb protein were lysed in EMSA lysis buer (10 mM Tris-HCl [pH 7.05], 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM ZnCl 2 , 100 mM Na 3 VO 4 , 1% Triton X-100) supplemented with a cocktail of proteases inhibitors (Complete TM ). The lysate was vortexed for 30 s, centrifuged at 48C for 30 min at 14 000 r.p.m. and stored at 7808C. For EMSAs, the Myb responsive element (MRE) from the mim-1 promoter (site A) (Ness et al., 1989) was generated by the hybridization of synthesized oligonucleo-tides 5'-TCGACACATTATAACGGTTTTTTAGC-3' and 5'-TCGAGCTAAAAAACCGTTATAATGTG-3'. The doublestranded oligonucleotide was labeled with a-32 P-dCTP (ICN) to a speci®c activity greater than 10 8 c.p.m./mg by end ®lling using Klenow fragment. The DNA-binding reaction was performed for 30 min at 278C with 1 ml of cell lysate and 0.1 ng of labeled oligonucleotide probe in reaction buer (10 mM Tris-HCl [pH 7.9], 50 mM NaCl, 1 mM EDTA, 10 mM dithiothreitol, 0.5% nonfat dry milk, 5% glycerol and 1 mg poly(dI-dC)). The DNA-protein complexes were separated by PAGE on a 5% gel in 0.256TBE buer (12.5 mM Tris-HCl [pH 8.5], 12.5 mM boric acid and 0.25 mM EDTA), dried and exposed to X-ray ®lm at room temperature for 4 ± 20 h.
